Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions

Experimental Hematology
Monica GunettiFranca Fagioli

Abstract

Several requirements need to be fulfilled for clinical use of expanded hematopoietic stem cells (HSCs). Because most cord blood (CB) samples are frozen in single bags and only an aliquot ( approximately 25%) of the blood can be expanded, the thawing and refreezing of samples must be validated in the current European and Italian Good Manufacturing Practice (eIGMP) conditions. Here, we describe in vitro and in vivo validation of the phase I/II protocol for CD34+ expansion of thawed CB units according to the current Cell Therapy Products (CTPs) Guidelines. CB units were thawed and 25% of the total volume was processed for CD34+ selection by CliniMACS. The 75% of the unit was immediately refrozen. CD34+ cells were expanded for 3 weeks with stem cell factor, Flt-3/Flk-2 ligand, thrombopoietin, and interleukin-6. In vitro results demonstrated that this culture system induces expansion of thawed CD34+ (median value = 8.3). In vivo data demonstrated that after culture, the final CTPs maintain their repopulating ability in nonobese diabetic severe combined immunodeficient (SCID) mice. Limiting dilution assays performed by injecting decreasing doses of expanded CD34+ cells revealed that the frequency of SCID repopulating cells after ex v...Continue Reading

References

May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·H E BroxmeyerE A Boyse
Oct 24, 1995·Proceedings of the National Academy of Sciences of the United States of America·P RubinsteinC E Stevens
May 1, 1994·British Journal of Haematology·A J NicolB A Bradley
Jul 30, 1999·Transfusion Medicine Reviews·P RebullaG Sirchia
Feb 15, 2001·Journal of Hematotherapy & Stem Cell Research·W PiacibelloM Aglietta
Jun 6, 2002·Proceedings of the National Academy of Sciences of the United States of America·Hiroshi MoriMel Greaves
Aug 13, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Elizabeth J ShpallIan K McNiece
Jun 6, 2006·Bone Marrow Transplantation·H SchoemansJ Wagner

❮ Previous
Next ❯

Citations

Mar 15, 2011·Journal of Cellular Biochemistry·Pedro Z AndradeJoaquim M S Cabral
Apr 9, 2013·Journal of Tissue Engineering and Regenerative Medicine·Pedro Z AndradeCláudia L da Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.